US 11,439,589 B2 · Emulsion eyedrops

Abstract

Provided are: emulsion eyedrops which have no concern with possible corneal injury induced by a nonionic surfactant, have excellent thermal stability and physical stability and can contain a sparingly water-soluble drug in an increased amount; and an emulsion eyedrops stabilization method. The emulsion eyedrops contain castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5. The emulsion eyedrops stabilization method is characterized by preparing emulsion eyedrops containing castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5.

Claims6

Dependent claims

Emulsion eyedrops comprising castor oil and poly(vinyl alcohol), wherein the concentration of the castor oil is 5 to 20 w/v %, the concentration of the poly(vinyl alcohol) is 2 to 7 w/v %, the ratio of the weight of the castor oil to the weight of the poly(vinyl alcohol) is 1.2 to 5,

wherein no nonionic surfactant is present,
wherein the average particle diameter of oil droplets contained in the emulsion eyedrops before the sterilization in the autoclave is 100 to 200 nm,
wherein the emulsion eyedrops do not contain water-soluble polymers other than poly(vinyl alcohol),
and wherein, when the emulsion eyedrops are sterilized in an autoclave at 121° C. for 20 minutes, the rate of change in the average particle diameter of oil droplets contained in the emulsion eyedrops before and after the sterilization in the autoclave is less than 3%.

1 more element

Dependencies are inferred from the claim text.

Emulsion eyedrops

Life of this patent

Emulsion eyedrops

Life of this patent

Abstract

Claims6